Immunic CEO on strong Q2 progress with vidofludimus calcium trials for MS

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive's Stephen Gunnion about the company’s second-quarter highlights, with a particular focus on clinical progress in its multiple sclerosis (MS) programs. The headline development was the promising results from the Phase 2 CALLIPER trial of vidofludimus calcium, Immunic’s lead asset in progressive MS. Vitt noted a 24% reduction in disability progression across the full study population, with over 30% reduction seen in patients with primary progressive MS. “That basically confirms the mode of action of the drug,” Vitt said, underlining its potential to slow disease progression. Vitt also addressed the completion of enrollment in the Phase 3 ENSURE trials, which are testing vidofludimus calcium in relapsing MS. These two twin studies now include 2,200 patients in total, with data expected by the end of next year. Further support came from long-term results in the EMPhASIS study, testing vidofludimus calcium in relapsing-remitting MS, where more than 90% of patients remained free of disability progression after nearly three years of treatment. Vitt highlighted the low discontinuation rates and long-term adherence as additional positive indicators. Finally, he commented on the company's strengthened financial position, citing recent capital raises as critical to progressing both Phase 3 trials. For more insightful updates from biotech leaders, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications so you never miss a story. #ImmunicInc #MultipleSclerosis #VidofludimusCalcium #MSResearch #CALLIPERStudy #ENSURETrial #Neuroprotection #BiotechNews #PharmaUpdates #ClinicalTrials